Cookies help us deliver our services. By using our services, you agree to our use of cookies. More information

Difference between revisions of "Lensu 2020 Preprints"

From Bioblast
(Created page with "{{Publication |title=Lensu S, Pariyani R, Mäkinen E, Yang B, Saleem W, Munukka E, Lehti M, Driuchina A, Linden J, Tiirola M, Lahti L, Pekkala S (2020) Prebiotic xylo-oligosac...")
 
Line 2: Line 2:
|title=Lensu S, Pariyani R, Mäkinen E, Yang B, Saleem W, Munukka E, Lehti M, Driuchina A, Linden J, Tiirola M, Lahti L, Pekkala S (2020) Prebiotic xylo-oligosaccharides targeting ''Faecalibacterium prausnitzii'' prevent high fat diet-induced hepatic steatosis in rats. Preprints 2020:2020090241.
|title=Lensu S, Pariyani R, Mäkinen E, Yang B, Saleem W, Munukka E, Lehti M, Driuchina A, Linden J, Tiirola M, Lahti L, Pekkala S (2020) Prebiotic xylo-oligosaccharides targeting ''Faecalibacterium prausnitzii'' prevent high fat diet-induced hepatic steatosis in rats. Preprints 2020:2020090241.
|info=[https://www.preprints.org/manuscript/202009.0241/v1 Open Access]
|info=[https://www.preprints.org/manuscript/202009.0241/v1 Open Access]
|authors=Lensu S, Pariyani R, Mäkinen E, Yang B, Saleem W, Munukka E, Lehti M, Driuchina A, Linden J, Tiirola M, Lahti L, Pekkala S
|authors=Lensu Sanna, Pariyani Raghunath, Maekinen Elina, Yang Baoru, Saleem Wisam, Munukka Eveliina, Lehti Maarit, Driuchina Anastasiia, Linden Jere, Tiirola Marja, Lahti Leo, Pekkala Satu
|year=2020
|year=2020
|journal=Preprints
|journal=Preprints
|abstract=Understanding the importance of gut microbiota (GM) in non-alcoholic fatty liver disease (NAFLD) has raised the hope for therapeutic microbes. We have shown that high hepatic fat associated with low abundance of ''Faecalibacterium prausnitzii'' in humans and further, administration of ''F. prausnitzii'' prevented NAFLD in mice. Here, we aimed to target ''F. prausnitzii'' by prebiotic xylo-oligosaccharides (XOS) to treat NAFLD. First, the effect of XOS on ''F. prausnitzii'' growth was assessed ''in vitro''. Then, XOS was supplemented or not with high (HFD) or low (LFD) fat-diet for 12-weeks in Wistar rats (n=10/group). XOS increased ''F. prausnitzii'' growth having only minor impact on the GM composition. When supplemented with HFD, XOS prevented hepatic steatosis. The underlying mechanisms involved enhanced hepatic β-oxidation and mitochondrial respiration. 1H-NMR analysis of caecal metabolites showed that compared to HFD, LFD group had healthier caecal short-chain fatty acid profile and the combination of HFD and XOS was associated with reduced caecal isovalerate and tyrosine, metabolites previously linked to NAFLD. Caecal branched-chain fatty acids associated positively and butyrate negatively with hepatic triglycerides. In conclusion, our study identifies ''F. prausnitzii'' as a possible target to treat NAFLD with XOS. The underlying preventive mechanisms involved improved hepatic oxidative metabolism.
|abstract=Understanding the importance of gut microbiota (GM) in non-alcoholic fatty liver disease (NAFLD) has raised the hope for therapeutic microbes. We have shown that high hepatic fat associated with low abundance of ''Faecalibacterium prausnitzii'' in humans and further, administration of ''F. prausnitzii'' prevented NAFLD in mice. Here, we aimed to target ''F. prausnitzii'' by prebiotic xylo-oligosaccharides (XOS) to treat NAFLD. First, the effect of XOS on ''F. prausnitzii'' growth was assessed ''in vitro''. Then, XOS was supplemented or not with high (HFD) or low (LFD) fat-diet for 12-weeks in Wistar rats (n=10/group). XOS increased ''F. prausnitzii'' growth having only minor impact on the GM composition. When supplemented with HFD, XOS prevented hepatic steatosis. The underlying mechanisms involved enhanced hepatic β-oxidation and mitochondrial respiration. H-NMR analysis of caecal metabolites showed that compared to HFD, LFD group had healthier caecal short-chain fatty acid profile and the combination of HFD and XOS was associated with reduced caecal isovalerate and tyrosine, metabolites previously linked to NAFLD. Caecal branched-chain fatty acids associated positively and butyrate negatively with hepatic triglycerides. In conclusion, our study identifies ''F. prausnitzii'' as a possible target to treat NAFLD with XOS. The underlying preventive mechanisms involved improved hepatic oxidative metabolism.
|keywords=Prebiotic, Oligosaccharides, Gut microbiota, Fatty liver, Metabolism, Mitochondria
|keywords=Prebiotic, Oligosaccharides, Gut microbiota, Fatty liver, Metabolism, Mitochondria
|editor=[[Plangger M]]
|editor=[[Plangger M]]
Line 11: Line 11:
{{Labeling
{{Labeling
|area=Respiration
|area=Respiration
|organism=Rat
|instruments=Oxygraph-2k
|instruments=Oxygraph-2k
|additional=2020-09
|additional=2020-09
}}
}}

Revision as of 19:27, 25 September 2020

Publications in the MiPMap
Lensu S, Pariyani R, Mäkinen E, Yang B, Saleem W, Munukka E, Lehti M, Driuchina A, Linden J, Tiirola M, Lahti L, Pekkala S (2020) Prebiotic xylo-oligosaccharides targeting Faecalibacterium prausnitzii prevent high fat diet-induced hepatic steatosis in rats. Preprints 2020:2020090241.

» Open Access

Lensu Sanna, Pariyani Raghunath, Maekinen Elina, Yang Baoru, Saleem Wisam, Munukka Eveliina, Lehti Maarit, Driuchina Anastasiia, Linden Jere, Tiirola Marja, Lahti Leo, Pekkala Satu (2020) Preprints

Abstract: Understanding the importance of gut microbiota (GM) in non-alcoholic fatty liver disease (NAFLD) has raised the hope for therapeutic microbes. We have shown that high hepatic fat associated with low abundance of Faecalibacterium prausnitzii in humans and further, administration of F. prausnitzii prevented NAFLD in mice. Here, we aimed to target F. prausnitzii by prebiotic xylo-oligosaccharides (XOS) to treat NAFLD. First, the effect of XOS on F. prausnitzii growth was assessed in vitro. Then, XOS was supplemented or not with high (HFD) or low (LFD) fat-diet for 12-weeks in Wistar rats (n=10/group). XOS increased F. prausnitzii growth having only minor impact on the GM composition. When supplemented with HFD, XOS prevented hepatic steatosis. The underlying mechanisms involved enhanced hepatic β-oxidation and mitochondrial respiration. H-NMR analysis of caecal metabolites showed that compared to HFD, LFD group had healthier caecal short-chain fatty acid profile and the combination of HFD and XOS was associated with reduced caecal isovalerate and tyrosine, metabolites previously linked to NAFLD. Caecal branched-chain fatty acids associated positively and butyrate negatively with hepatic triglycerides. In conclusion, our study identifies F. prausnitzii as a possible target to treat NAFLD with XOS. The underlying preventive mechanisms involved improved hepatic oxidative metabolism. Keywords: Prebiotic, Oligosaccharides, Gut microbiota, Fatty liver, Metabolism, Mitochondria Bioblast editor: Plangger M


Labels: MiParea: Respiration 


Organism: Rat 




HRR: Oxygraph-2k 

2020-09